390
Participants
Start Date
September 30, 2025
Primary Completion Date
March 31, 2029
Study Completion Date
March 31, 2029
Cemiplimab
Cemiplimab, 350 mg i.v., every 3 weeks (±3 days), for 4 cycles, followed by 700 mg i.v., every 6 weeks (±1 week) for 6 cycles or until relapse or unacceptable toxicities, whichever occurs first.
Wien AKH, Vienna
North Estonia Medical Centre Foundation, Talinn
CHU d'Angers, Angers
Centre hospitalier d'Avignon, Avignon
Evangelische Lungenklinik Berlin, Buch
Ruhrlandklinik Essen, Essen
LMU München, München
Pius Hospital, University Medicine Oldenburg, Oldenburg
Beaumont Hospital, Dublin
St James's Hospital, Dublin
SS Antonio e Biagio e Cesare Arrigo Hospital, Alessandria
IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Instituto Europeo di Oncologia (IEO), Milan
AOU Maggiore della Carità, Novara
Instituto Oncologico Veneto IRCCS, Padua
Fondazione IRCCS Policlinico S. Matteo, Pavia
University of Perugia, AO SM Misericorida Perugia, Perugia
Azienda ospedaliero-universitaria Senese Siena, Siena
AULSS2 Marca Trevigiana Treviso, Treviso
Universita di Verona - Department of Medicine, Verona
National University Hospital, Singapore
Complejo Hospitalario Universitario, A Coruña
Hospital General Universitario Dr. Balmis de Alicante, Alicante
Hospital Universitario Cruces, Barakaldo
Hospital de La Santa Creu I Sant Pau, Barcelona
Hospital Universitario Vall D'Hebron, Barcelona
Hospital Clínico San Cecilio de Granada, Granada
Hospital Universitario de Jerez de La Frontera, Jerez de la Frontera
Hospital Clínico San Carlos, Madrid
Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife
Hospital General Universitario de Valencia, Valencia
University Hospital Basel, Basel
Kantonsspital Winterthur, Winterthur
Regeneron Pharmaceuticals
INDUSTRY
ETOP IBCSG Partners Foundation
NETWORK